Tekla Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Tekla Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$576K	Hold	52,067	–	–	0.02%	138
2023 Q1	$699K	Hold	52,067	–	–	0.03%	139
2022 Q4	$644K	Hold	52,067	–	–	0.02%	142
2022 Q3	$726K	Hold	52,067	–	–	0.03%	138
2022 Q2	$719K	Hold	52,067	–	–	0.03%	141
2022 Q1	$847K	Hold	52,067	–	–	0.03%	149
2021 Q4	$848K	Hold	52,067	–	–	0.03%	150
2021 Q3	$773K	Sell	52,067 -25,000	-32%	-$400K	0.02%	155
2021 Q2	$1.54M	Hold	77,067	–	–	0.05%	162
2021 Q1	$1.78M	Hold	77,067	–	–	0.06%	164
2020 Q4	$1.9M	Hold	77,067	–	–	0.07%	161
2020 Q3	$3.19M	Hold	77,067	–	–	0.12%	124
2020 Q2	$3.69M	Buy	77,067 +42,653	+124%	+$3.29M	0.14%	122
2020 Q1	$2.17M	Hold	34,414	–	–	0.1%	130
2019 Q4	$4.26M	Hold	34,414	–	–	0.16%	120
2019 Q3	$2.28M	Sell	34,414 -19,443	-36%	-$1.31M	0.1%	131
2019 Q2	$4.29M	Sell	53,857 -5,418	-9%	-$485K	0.17%	96
2019 Q1	$6.63M	Buy	59,275 +45,927	+344%	+$5.02M	0.27%	80
2018 Q4	$1.34M	Buy	+13,348	New	+$1.38M	0.06%	147
2017 Q4	–	Sell	-123,200	Closed	-$7.15M	–	165
2017 Q3	$7.15M	Buy	+123,200	New	+$13.3M	0.26%	72

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Tekla Capital Management's ICPT Position: Q2 2023 in Review

Tekla Capital Management held its Intercept Pharmaceuticals, Inc. (ICPT) position steady in Q2 2023 at 52,067 shares worth $576K. The position accounts for 0.02% of the portfolio, ranked #138.

Tekla Capital Management first reported a position in ICPT in Q3 2017 and has held it in 20 quarters since. The position peaked at $7.15M in Q3 2017. 126 funds tracked by Wall St. Rank hold ICPT as of Q2 2023.

Tekla Capital Management held 52,067 shares of Intercept Pharmaceuticals, Inc. worth $576K as of Q2 2023.
Tekla Capital Management left its Intercept Pharmaceuticals, Inc. share count unchanged in Q2 2023.
Intercept Pharmaceuticals, Inc. made up 0.02% of Tekla Capital Management's portfolio in Q2 2023, its #138 holding.
Tekla Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2017 and has held it in 20 quarters since.
Tekla Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $7.15M in Q3 2017.
126 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.